News By Tag
News By Location
Wareham Development announces more new leases in Emeryville and Berkeley
Dynavax Technologies is second tenant to move to new state-of-the-art building in EmeryStation research campus; Caribou Biosciences expands at 2929 Seventh Street in Berkeley.
Dynavax Technologies, Inc., a long-time tenant of Wareham Development, plans to move its 41,000 SF headquarters in Wareham's Aquatic Park Center campus at the 2929 Seventh Street into a new 75,000 SF office and laboratory on the sixth and seventh floors at EmeryStation West in late 2Q 2019.
"We are thrilled about the growth of Dynavax and the supporting part we can play in it. We are delighted to welcome their team to EmeryStation West," says Wareham partner Geoffrey B. Sears. "We have built the project to the highest quality research and office building standards, and are pleased the market recognizes that," he adds.
"We are a company with East Bay roots along the East Shore. Wareham has been landlord to Dynavax from its very beginning in 1998. We are excited that our expansion needs are met in their beautiful new EmeryStation West building, and happy that our successful relationship with Wareham continues," says Eddie Gray, Chief Executive Officer and Director.
Wareham Development was represented by the Kidder Mathews team of Timothy Mason, James Bennett and Eric Bluestein. Dynavax was represented by Scott Stone of Cresa and Mark Moser of Savills Studley.
Concurrently, Wareham Development announced an existing tenant, Caribou Biosciences, Inc., will expand into an additional 23,500 square feet of space vacated by Dynavax at 2929 Seventh Street, where it is headquartered within Wareham's Aquatic Park Center campus in West Berkeley. Caribou will, upon this expansion, occupy approximately 50,000 square feet within the building.
"Caribou started out in a basement at the University of California, Berkeley incubator and quickly moved into Wareham's QB3 East Bay Innovation Center space in our Aquatic Park Center campus," says Chris Barlow, Wareham's partner in charge of the Berkeley portfolio. "As Caribou continued its rapid growth, we are delighted to have been able to meet their incremental expansion needs at 2929 Seventh Street," he adds.
"Our commitment to Berkeley and the East Bay is firm. About 60% of our employees live within a 10-mile radius of our facility and almost 20% bike to work using the designated bike paths in Berkeley and Emeryville,"
The world-class addition to Wareham's highly-successful 2-million SF EmeryStation research and tech campus was designed to meet LEED Gold standards. Its seven levels of laboratory and office space sit above a two-story transit and 125-car parking podium.
The construction team, led by Perkins + Will, one of the preeminent firms specializing in the design of laboratories and office for the life science and tech sectors, included Nova Partners, DPR Construction, Rutherford + Chekene, and Interface Engineering.
The new East Bay/Transbay transit center at the street level will serve Amtrak's Capitol Corridor commuter route from Sacramento to San Jose. Bus bays allow passengers to hop off the train and access last-mile transit options including AC Transit to the new San Francisco Transbay facility or elsewhere, to the free EmeryGoRound shuttle to BART and around Emeryville, or to taxis, limos, car, and bike shares.
In its 40th year, Wareham Development is one of the largest privately-held real estate development and property management companies in the Bay Area. It has been in the forefront of the transformation of Emeryville and Berkeley into an international hub of headquarters for research and tech ventures, most of whom reside in its EmeryStation and Aquatic Park Center campuses.
Wareham's mixed-use, multi-tenanted research and tech campuses in Emeryville, Berkeley, Richmond, and Palo Alto award-winning architecture, spectacular landscaping, abundant tenant-friendly amenities, and superb property management—all hallmarks of Wareham projects.
Wareham tenants encompass the spark and promise of small companies on the verge of growth, and large corporations whose fortunes span the globe.
"We are proud of our associations with all of our tenants, and feel deeply privileged to play a role in their success," says Sears.
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant)
Caribou was founded by scientists from the University of California, Berkeley to drive the commercialization of applications based on the remarkable nucleic acid modification capabilities found in prokaryotic CRISPR systems. The Caribou CRISPR-Cas technology platform has the potential to revolutionize the future of therapeutics, agriculture, biological research, and industrial biotechnology with a gene editing technology platform that enables simple, flexible targeting of virtually any site in a genome.